In Vivo Efficacy of Recombinant Leukotactin-1 against Cyclophosphamide

• Published in: Biotechnology and bioprocess engineering 2004, 9(1), , pp.7-11
• Main Authors: 윤엽, 김동일, 박두홍, Gue-Wha Lee, Kong Ju Lee, Eun Young Chun, In Whan Lim, Eun Kyoung Lee, Mu Rim Choi
• Format: Article
• Language: Korean
• Subjects: 생물공학
• ISSN: 1226-8372; 1976-3816

Leukotactin-1 (Lkn-1), a human CC chemokine, has been demonstrated to induce chemotaxis of neutrophils, monocytes, eosinophils and lymphocytes and has been shown to suppress colony formation of hematopoietic stem and progenitor cells (HSPC) in vitro and in vivo. The temporal suppression of HSPC by chemokines could potentially be applicable for various indications, such as the protection of HSPC from the several anti-proliferating chemotherapeutics in cancer treatments. In order to evaluate the protective effects on myeloid progenitor cells, the recombinant Lkn-1 was produced by Pichia pastoris and tested with cyclophosphamide, cytotoxic chemotherapeutics. The pretreatment of Lkn-1 increased the number of HSPC in bone marrow as well as the potency of resulting progenitor cells after the treatment of cyclophosphamide. After the first cycle of cyclophosphamide treatment these protections of HSPC correlated with the increased number of white blood cells and neutrophils in the peripheral blood. In lethal conditions created by the repeated administration of cyclophosphamide, the treatment of Lkn-1 enhanced the survival of mice, suggesting the potential use of Lkn-1 as the protective agent for HSPC from various cytotoxic insults. KCI Citation Count: 1